Core Insights - Dongfulong (300171) reported a revenue of 2.429 billion yuan for the first half of 2025, representing a year-on-year growth of 6.01% and a net profit attributable to shareholders of 45.9195 million yuan [1] - The company plans to distribute a cash dividend of 0.30 yuan per 10 shares (tax included) to all shareholders [1] Business Segments - Dongfulong operates in four main segments: Biopharmaceuticals, Formulations, Engineering Solutions, and Food Equipment, with revenues of 1.091 billion yuan, 0.724 billion yuan, 0.223 billion yuan, and 0.222 billion yuan respectively in the first half of 2025 [1] - The Food Equipment segment saw a significant revenue increase of 73.77% year-on-year [1] International Business - The company achieved international business revenue of 0.805 billion yuan, accounting for 33.14% of total revenue, with a year-on-year growth of 63.25% [2] - The gross margin for international business was 48.03%, an increase of 1.84% compared to the same period last year [2] - Dongfulong successfully delivered key projects in the pharmaceutical equipment sector, enhancing its brand recognition and market share internationally [2]